Il Messaggiere - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
CMSC 0.74% 24.23 $
SCS -0.42% 16.6 $
RIO -1.32% 68.34 $
RBGPF 0% 79.09 $
BCC 2.55% 72.86 $
CMSD 0.53% 24.51 $
JRI 0.14% 13.97 $
RYCEF 0.39% 15.31 $
NGG -0.29% 76.39 $
BCE 0.29% 23.93 $
BTI -1.53% 50.39 $
VOD -1.3% 11.51 $
RELX 0.39% 46.29 $
GSK -0.41% 43.94 $
BP -0.18% 33.16 $
AZN -0.78% 83.22 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

A.Bruno--IM